- Home
- GYRE vs YSG Comparison
GYRE vs YSG Comparison
Compare GYRE & YSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- YSG
- Stock Information
- Founded
- GYRE 2002
- YSG 2016
- Country
- GYRE United States
- YSG China
- Employees
- GYRE N/A
- YSG N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- YSG Package Goods/Cosmetics
- Sector
- GYRE Health Care
- YSG Consumer Discretionary
- Exchange
- GYRE Nasdaq
- YSG Nasdaq
- Market Cap
- GYRE 897.1M
- YSG 889.0M
- IPO Year
- GYRE N/A
- YSG 2020
- Fundamental
- Price
- GYRE $7.90
- YSG $10.01
- Analyst Decision
- GYRE Strong Buy
- YSG
- Analyst Count
- GYRE 1
- YSG 0
- Target Price
- GYRE $18.00
- YSG N/A
- AVG Volume (30 Days)
- GYRE 96.3K
- YSG 419.4K
- Earning Date
- GYRE 11-12-2025
- YSG 08-21-2025
- Dividend Yield
- GYRE N/A
- YSG N/A
- EPS Growth
- GYRE N/A
- YSG N/A
- EPS
- GYRE 0.02
- YSG N/A
- Revenue
- GYRE $102,189,000.00
- YSG $522,879,337.00
- Revenue This Year
- GYRE $18.39
- YSG $17.93
- Revenue Next Year
- GYRE $48.26
- YSG $12.79
- P/E Ratio
- GYRE $469.46
- YSG N/A
- Revenue Growth
- GYRE N/A
- YSG 11.53
- 52 Week Low
- GYRE $6.11
- YSG $3.01
- 52 Week High
- GYRE $19.00
- YSG $11.57
- Technical
- Relative Strength Index (RSI)
- GYRE 51.30
- YSG 54.06
- Support Level
- GYRE $7.55
- YSG $10.01
- Resistance Level
- GYRE $8.56
- YSG $10.70
- Average True Range (ATR)
- GYRE 0.51
- YSG 0.56
- MACD
- GYRE -0.01
- YSG 0.05
- Stochastic Oscillator
- GYRE 57.14
- YSG 66.50
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.